Regional variation in the prescribing for diabetes and use of secondary preventative therapies in Ireland

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 8, 2005, Pages 537-544

  Usher, Cara ^a   Bennett, Kathleen ^a   Feely, John ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Diabetes; Prescribing; Regional variation; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH PROMOTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRELAND; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; REGIONALIZATION; SCREENING TEST; SECONDARY PREVENTION; SEX DIFFERENCE; SOCIOECONOMICS; STANDARDIZATION;

ADULT; AGE FACTORS; AGED; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRELAND; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ODDS RATIO; PRESCRIPTIONS, DRUG; SEX FACTORS;

EID: 23844474479     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1104     Document Type: Article

References (26)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. UK Prospective Diabetes Study Group (UKPDS). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12 year cardiovascular risk mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
4. Kannel W, McGee D. Diabetes and Cardiovascular disease: the Framingham Study. JAMA 1979; 241: 2035-2038.
5. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br Med J 1983; 287: 867-870.
6. Cowie CC, Eberhardt MS. Sociodemographic characteristics of persons with diabetes. In Diabetes in America (2nd edn). National Diabetes Data Group (eds). National Institutes of Health Publication: Bethesda, MD, 1995: 95-1468.
7. Department of Health and Children, Ireland. Building Healthier Hearts: a report of the Cardiovascular Health strategy group, 1999.
8. Irish College of General Practitioners Diabetes Task Group. Guidelines for Diabetes Care in the Community, Dublin, 2000.
9. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Reccommendations of the Second Joint Task Force of European and other societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
11. Bennett K, Williams D, Feely J. Inequalities in the prescribing of secondary preventative therapies for Ischaemic Heart Disease in Ireland. Ir Med J 2002; 95: 169-172.
12. Bennett K, Williams D, Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 2003; 58: 835-841.
13. WHO. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs), Geneva, 2001.
14. NcNally PG. Epidemiology of heart disease in type 1 and 2 diabetes. In Diabetes and Cardiovascular Complications, McNally PG (ed.). Science: London, 1999.
15. Johnson Z, Hayes C, Dack P. The standardized prescribing ratio - a new method for comparing prescribing between GPs, controlling for patient age and sex. Pharmacoepidemiol Drug Safe 1997; 6: 337-345.
16. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - 1: prevention of death, myocardial infarction, and stroke and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
17. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. Br Med J 1998; 317: 1134-1135.
18. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Socioeconomic status and type 2 diabetes in African Americans and non-Hispanic white women and men: evidence from the third National Health and Nutrition Examination survey. Am J Public Health 2001; 91: 76-83.
19. Hoskins PL, Fowler PM. Sharing the care of diabetic patients between hospital and general practioners; does it work. Diabet Med 1993; 101: 81-86.
20. Dunn N, Pickering R. Does good practice organization improve the outcome of care for diabetic patients? Brit J Gen Pract 1998; 1237-1240.
21. McLaughlin T, Soumerai S, Willison D, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for under treatment in women and the Elderly. Arch Intern Med 1996; 156: 799-805.
22. Hippesley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. Br Med J 2001; 322: 832.
23. Tobin JN, Wassertheil-Smoller S, Wexler JP, et al. Sex bias in considering coronary bypass surgery. Ann Intern Med 1987; 107: 19-25.
24. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. Br Med J 1997; 315: 1059.
25. Robertson JR. New British guidelines on the clinical management of drug misuse and drug dependence. Addiction 2000; 95: 325-326.
26. Diabetes Service Development Group Report. Diabetes care; securing the future, 2000.